 Double-Blind Method
"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 19 | 19 | | 1997 | 0 | 18 | 18 | | 1998 | 0 | 18 | 18 | | 1999 | 0 | 19 | 19 | | 2000 | 0 | 20 | 20 | | 2001 | 0 | 22 | 22 | | 2002 | 0 | 27 | 27 | | 2003 | 1 | 29 | 30 | | 2004 | 0 | 39 | 39 | | 2005 | 0 | 36 | 36 | | 2006 | 0 | 43 | 43 | | 2007 | 0 | 33 | 33 | | 2008 | 0 | 47 | 47 | | 2009 | 0 | 50 | 50 | | 2010 | 0 | 48 | 48 | | 2011 | 0 | 55 | 55 | | 2012 | 0 | 55 | 55 | | 2013 | 0 | 56 | 56 | | 2014 | 1 | 85 | 86 | | 2015 | 0 | 72 | 72 | | 2016 | 0 | 79 | 79 | | 2017 | 0 | 76 | 76 | | 2018 | 0 | 81 | 81 | | 2019 | 0 | 82 | 82 | | 2020 | 0 | 82 | 82 | | 2021 | 0 | 69 | 69 | | 2022 | 0 | 46 | 46 | | 2023 | 0 | 51 | 51 | | 2024 | 0 | 67 | 67 | | 2025 | 0 | 91 | 91 | | 2026 | 0 | 9 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Greenbaum CJ, Long SA, Gitelman SE, Gaglia JL, Daniels M, Brusko TM, Lord S, Bundy BN, Krischer JP, Haller MJ, Steck AK, DiMeglio LA, Evans-Molina C, Moran A, Prahalad P, Wilson DM, Russell WE, Sherr JL, Raskin P, Clements MA, Moore WV, Libman I, Wassermann K, von Herrath M, Bergholdt R, Hastrup H, Kobernat SE, Kus AM, Tung LW, Goland RS, Herold KC. Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes. Diabetes. 2026 Mar 01; 75(3):506-518.
-
Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Goldberg AC, Brunham LR, Wuerdeman E, Neild AL, Kling D, Hsieh A, Butters J, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Szarek M, Balinskaite V, Davidson MH. Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
-
Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F. Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. Eur Heart J. 2026 Feb 11; 47(6):683-697.
-
Kpetigo AD, Alexandre M, Camara A, Beavogui A, Doumbia S, Kieh M, Leigh B, Sow S, Wittkop L, Soutthiphong AA, Berry IM, Fleck S, Akoo P, Hamze B, Watson-Jones D, Kuhn JH, Greenwood B, Richert L, Yazdanpanah Y, Lévy Y, Thiébaut R, Prague M, Lhomme E. Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial. PLoS Negl Trop Dis. 2026 Jan; 20(1):e0013950.
-
Ustianowski A, Levin MJ, De Wit S, Launay O, Veekmans B, Rampling T, Sullivan JG, Vishnepolsky M, Wijewardane P, Fawadleh Y, Zhang H, Li M, Wickramarachchi D, Sharbaugh A, Beavon R, Thissen J, Hirao L, Dzutseva V, Seegobin S, Streicher K, Kiazand A, Esser MT, Chang LJ, Perez JL, Cohen TS. Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study. Clin Drug Investig. 2026 Feb; 46(2):207-219.
-
Biernacki K, Zhai T, Hill J, McConnell E, Salmeron BJ, Kaiser RH, Janes AC. From rest to focus: pharmacological modulation of the relationship between resting state dorsal attention network dynamics and task-based brain activation. Neuropsychopharmacology. 2026 Apr; 51(5):926-933.
-
Morimoto K, Chalmers JD, Burgel PR, Daley CL, De Soyza A, Mauger D, Metersky ML, Zhang X, Li S, Goto Y, Teper A, Fernandez C, Hasegawa N. Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial. Respir Investig. 2026 Mar; 64(2):101357.
-
Stein Gold L, Gottlieb AB, Armstrong AW, Alkousakis T, Bissonnette R, Langley RG, Krueger J, Papp K, Choi O, Rowland K, Chan D, Jeyarajah J, Park-Wyllie L, Gao LL, Gordon KB, Merola JF, Lebwohl MG, Strober B. SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. Br J Dermatol. 2026 01 06; 194(1):25-36.
-
Chu DS, Tsui E, Rifkin LM, Palestine AG, Rich C, Thorne JE, Haim-Langford D, Milman Z, Fulcher E, Neumann R, DE Smet MD. Dazdotuftide: Novel Treatment for Noninfectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical Trial. Am J Ophthalmol. 2026 Apr; 284:78-87.
-
Cole RM, Colombo E, Angelotti A, Sparagna GC, Choriego RE, Jimenez-Flores R, Ni A, Belury MA. Feasibility Study of Soybean Oil-Fortified Foods to Alter Blood Content of Linoleic Acid and Body Weight: A Randomized Double-Masked Placebo-Controlled Crossover Trial. J Nutr. 2026 Feb; 156(2):101288.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|